$77.83
6.87% yesterday
Nasdaq, Nov 25, 10:05 pm CET
ISIN
US2521311074
Symbol
DXCM
Sector

DexCom, Inc. Stock price

$77.83
+4.39 5.98% 1M
-49.54 38.89% 6M
-46.26 37.28% YTD
-36.15 31.72% 1Y
-71.82 47.99% 3Y
+21.13 37.27% 5Y
+65.15 513.92% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+5.00 6.87%
ISIN
US2521311074
Symbol
DXCM
Sector

Key metrics

Market capitalization $30.40b
Enterprise Value $30.50b
P/E (TTM) P/E ratio 46.66
EV/FCF (TTM) EV/FCF 57.01
EV/Sales (TTM) EV/Sales 7.71
P/S ratio (TTM) P/S ratio 7.69
P/B ratio (TTM) P/B ratio 15.36
Revenue growth (TTM) Revenue growth 16.19%
Revenue (TTM) Revenue $3.95b
EBIT (operating result TTM) EBIT $628.00m
Free Cash Flow (TTM) Free Cash Flow $535.00m
Cash position $2.49b
EPS (TTM) EPS $1.67
P/E forward 50.17
P/S forward 7.57
EV/Sales forward 7.59
Short interest 2.71%
Show more

Create a Free Account to create an DexCom, Inc. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

DexCom, Inc. Stock Analysis

Analyst Opinions

27 Analysts have issued a DexCom, Inc. forecast:

21x Buy
78%
6x Hold
22%

Analyst Opinions

27 Analysts have issued a DexCom, Inc. forecast:

Buy
78%
Hold
22%

Financial data from DexCom, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3,954 3,954
16% 16%
100%
- Direct Costs 1,513 1,513
22% 22%
38%
2,441 2,441
13% 13%
62%
- Selling and Administrative Expenses 1,055 1,055
5% 5%
27%
- Research and Development Expense 546 546
12% 12%
14%
840 840
24% 24%
21%
- Depreciation and Amortization 212 212
25% 25%
5%
EBIT (Operating Income) EBIT 628 628
24% 24%
16%
Net Profit 681 681
81% 81%
17%

In millions USD.

Don't miss a Thing! We will send you all news about DexCom, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DexCom, Inc. Stock News

Positive
The Motley Fool
2 days ago
It's not always easy to be a long-term investor, particularly when contending with the natural cyclicality that the stock market presents if you buy and hold through bull as well as bear markets.
Positive
Barrons
7 days ago
If you want to monitor your vital signs like an Olympic athlete, you should welcome a pact between glucose-monitor vendor DexCom and Oura smart rings.
Positive
Reuters
7 days ago
Medical device maker Dexcom said on Tuesday it will invest $75 million in Ōura's latest funding round, valuing the smart ring maker at over $5 billion.
More DexCom, Inc. News

Company Profile

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Sayer
Employees 9,600
Founded 1999
Website www.dexcom.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today